Cargando…
Management of Bevacizumab-Induced Proteinuria Using an Angiotensin Receptor Blocker (ARB) in a Neurofibromatosis Type 2 (NF-2) Patient With Vestibular Schwannoma
Neurofibromatosis type 2 (NF-2) is a genetic condition that by definition includes bilateral vestibular schwannoma, a non-malignant lesion also known as acoustic neuroma. Patients often develop hearing impairment and hearing loss as a result of the involvement of the vestibulocochlear nerve bilatera...
Autores principales: | Omene, Egiroh E, Easaw, Jay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613429/ https://www.ncbi.nlm.nih.gov/pubmed/37905291 http://dx.doi.org/10.7759/cureus.46202 |
Ejemplares similares
-
Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients
por: FUJII, Masazumi, et al.
Publicado: (2020) -
Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis
por: Bachir, Suha, et al.
Publicado: (2021) -
The impact of stereotactic radiosurgery in the management of neurofibromatosis type 2-related vestibular schwannomas
por: Lustgarten, Leonardo
Publicado: (2013) -
Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients
por: Webb, M J, et al.
Publicado: (2023) -
From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy
por: Matsoukas, John, et al.
Publicado: (2021)